Watson Pharmaceuticals (WPI +1.3%) is on track to announce a deal to buy Swiss-based Actavis for ~$6B by the end of April, creating one of the world's biggest producers of generic drugs, Reuters reports. Watson believes a move would help it compete more effectively against rivals like Teva and Novartis unit Sandoz.
Watson Pharmaceuticals (WPI +1.3%) is on track to announce a deal to buy Swiss-based Actavis for...
From other sites
Video at CNBC.com (Nov 19, 2015)
Video at CNBC.com (Sep 21, 2015)
Video at CNBC.com (Aug 6, 2015)
Video at CNBC.com (Jul 27, 2015)
at CNBC.com (Feb 18, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs